PC
CLLS

PA Capital’s Cellectis CLLS Stock Holding History

PA Capital’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$224K Sell
12,103
-5,948
-33% -$106K 0.16% 155
2020
Q2 		$321K Buy
+18,051
New +$275K 0.23% 121

Other funds holding CLLS

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

PA Capital's CLLS Position: Q3 2020 in Review

PA Capital reduced its Cellectis (CLLS) stake by 33% in Q3 2020, selling an estimated $106K and leaving 12,103 shares worth $224K. The position accounts for 0.16% of the portfolio, ranked #155.

PA Capital first reported a position in CLLS in Q2 2020 and has held it in 2 quarters since. The position peaked at $321K in Q2 2020. 74 funds tracked by Wall St. Rank hold CLLS as of Q3 2020.

  • PA Capital held 12,103 shares of Cellectis worth $224K as of Q3 2020.
  • PA Capital sold 5,948 Cellectis shares in Q3 2020, an estimated $106K.
  • Cellectis made up 0.16% of PA Capital's portfolio in Q3 2020, its #155 holding.
  • PA Capital first reported a position in Cellectis in Q2 2020 and has held it in 2 quarters since.
  • PA Capital's Cellectis position peaked at $321K in Q2 2020.
  • 74 funds tracked by Wall St. Rank held Cellectis as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.